1. Introduction {#sec1}
===============

Left hepatic trisectionectomy (LHT) was first described in 1982 by Starzl and colleagues \[[@bib1]\] and later by Blumgart in 1993 \[[@bib2]\]. The International Hepato-Pancreato-Biliary Association (IHPBA) consensus statement \[[@bib3]\] defines the resection as excision of Couinaud segments II, III, IV, V and VIII, with or without segment I. The procedure is reserved for large left sided and central tumours that extend to involve the right anterior sectional portal pedicular structures.

Despite its' initial description the procedure has gained slow acceptance and outcomes are limited to small case series. The first large series on peri-operative outcomes was published in 1999 ^4^, and found an increased rate of morbidity and mortality, 53% and 8% respectively, when compared with other less extensive hepatic resections. However, it highlighted the utility of LHT in lesions that were considered to previously be unresectable \[[@bib4]\]. Other series have also demonstrated an increased morbidity and mortality rate with LHT when compared with other hepatectomies \[[@bib5],[@bib6]\]. The increase in morbidity is attributable to the more extensive nature of the disease being treated, and the extent of hepatic resection. The procedure is therefore reserved for those with a significant tumour burden.

Long-term outcomes on patients undergoing LHT support the use of this procedure. Data regarding 1, 3 and 5-year survival has been shown to be comparable with other less extensive hepatic resections. The 1, 3 and 5 year survival data for patients with all malignancies undergoing LHT has been found to be \>70%, 50% and 30% respectively in several papers \[[@bib5], [@bib6], [@bib7], [@bib8]\].

The aim of this study was to assess the short and long-term outcomes of LHT for patients with cholangiocarcinoma (CCA) or large volume liver metastases at our institution, and to identify any factors associated with morbidity and mortality.

2. Methods {#sec2}
==========

All patients undergoing LHT at RSCH, Guildford, UK from September 1996 to October 2015 were included. The research registry number for the study was: researchregistry5031. Demographic data, ASA fitness grade, pre-operative intervention, neo-adjuvant chemotherapy, intra-operative and post-operative data, post-operative complications and mortality were extracted from a prospectively maintained database. Complications were graded according to the Clavien Dindo classification of surgical complications \[[@bib9]\]. This work is fully compliant with STROCSS criteria \[[@bib10]\]. The study is registered with the Research Registry and its unique identification number is researchregistry5031.

2.1. Statistical analysis {#sec2.1}
-------------------------

Categorical data were analysed by means of Pearson\'s χ2 test. The Kaplan--Meier method was used to analyse overall survival (OS). Univariate analysis was performed to show factors that had a significant influence on postoperative morbidity, 90-day mortality, and disease-specific overall survival (OS) in the univariable analysis. Date of last follow-up was December 2016. All statistical analyses were performed using SPSS® for Windows®/Mac™ version 21 (IBM, USA), and statistical significance was taken at the 5% level.

3. Results {#sec3}
==========

During the study period, 1570 hepatic resections were performed at our HPB unit. Of these, 28 (2%) patients underwent LHT. Pre-operatively all patients were evaluated with contrast enhanced CT scan±MRI. The future liver remnant volume was assessed at our MDT and decisions were then made regarding their management. The majority of these patients had CRLM (n = 20; 72%), followed by CCA (n = 4; 14%) and then other pathologies including metastatic breast cancer, hepatocellular carcinoma and NET (n = 4; 14%). In total, there were 18 male and 10 female patients. The median age was 60 years (range 43--76 years). ASA grade was I in 6 patients (21%); II in 20 patients (71%) and III in 2 patients (7%).

Nineteen patients (68%) received neo-adjuvant chemotherapy. Of these, 17 (85%) patients had a diagnosis of CRLM, whilst 2 (50%) patients with other pathologies (metastatic breast cancer and NET) also received neo-adjuvant chemotherapy. No patients with CCA received neo-adjuvant chemotherapy treatment ([Table 1](#tbl1){ref-type="table"}). Data on the exact type of adjuvant chemotherapy after surgery was not available, as many patients return to their referring units for oncological treatment. Prior to undergoing resection, one (5%) patient with CRLM underwent pre-operative portal vein embolisation (PVE) to increase the size of future liver remnant (FLR). One patient (25%) with a diagnosis of hilar cholangiocarcinoma was found to be jaundiced pre-operatively and underwent subsequent biliary drainage with endoscopic retrograde cholangio-pancreatography (ERCP), followed by percutaneous transhepatic cholangio-pancreatography (PTC) drainage. At our institution, any patient with significant jaundice and/or cholangitis undergoes pre-operative biliary drainage.Table 1Demographics of all patients undergoing LHT according to pathology.Table 1Colorectal liver metastases (CRLM)Cholangiocarcinoma (CC)Other pathology (HCC, NET, breast)**Number of procedures**n = 20/28 (72%)n = 4/28 (14%)n = 4/28 (14%)**M:F ratio**15:51:32:2**ASA gradeI**321**II**1613**III**11--**Neo-adjuvant chemotherapy**n = 17/20 (85%)n = 0n = 2/4 (50%)

The resections performed are shown in [Table 2](#tbl2){ref-type="table"}. Median duration of surgery was 270 min (range 210--540mins). Median blood loss in patients undergoing LHT was 750 ml (range 400--2400 ml). In total 6 patients (21%) received a peri-operative transfusion, of whom 4 (14%) received an intra-operative blood transfusion, whilst 2 (7%) patients received a blood transfusion post-operatively. The median number of units transfused in all patients undergoing LHT was 0 units (range 0--2). All six patients that required peri-operative transfusion received 2 units of packed red cells each ([Table 3](#tbl3){ref-type="table"}).Table 2Operations performed on patients with colorectal liver metastases, cholangiocarcinoma and other pathology.Table 2Colorectal liver metastases (CRLM)Cholangiocarcinoma (CC)Other pathology (HCC, NET, breast)**L hepatectomy ext 5 + 8**n = 13/20 (65%)--n = 1/4 (25%)**L hepatectomy ext 1, 5 + 8**n = 2/20 (10%)n = 4/4 (100%)n = 1/4 (25%)**L hepatectomy ext 5 + 8 plus wedge resection**n = 4/20 (20%)--n = 1/4 (25%)**L hepatectomy ext 1, 5 + 8 plus wedge resection**n = 1/20 (5%)--n = 1/4 (25%)Table 3Operative details for patients with colorectal liver metastases, cholangiocarcinoma and other pathology.Table 3Colorectal liver metastases (CRLM)Cholangiocarcinoma (CC)Other pathology (HCC, NET, breast)**Median duration of surgery (minutes)**270 min (range 210--480 min)320 min (range 390--585 min)255 min (210--540 min)**Median blood loss (mls)**700 ml (range 300--2400 ml)650 ml (500--1500 ml)1800 ml (1200--2000 ml)**Number of patients transfused intra-operatively**n = 3/20 (15%)n = 2/4 (50%)n = 1/4 (25%)**Median number of units transfused intra-operatively**0 (range 0--2)0 (range 0--2)--**Number of patients transfused post-operatively**n = 1/20 (5%)--n = 1/4 (25%)**Median number of units transfused post-operatively**0 (range 0--2)--0 (range 0--2)

The incidence of post-operative morbidity was 21% ([Table 4](#tbl4){ref-type="table"}). Six patients developed post-operative complications. Morbidity included chest infection, bile leak and post-hepatectomy liver failure. One patient developed a significant bile leak and returned to theatre for laparotomy, washout and drainage. One patient developed severe post-hepatectomy liver failure and ultimately died within 90 days. The median length of stay in hospital was 9 days (range 4--80 days).Table 4Complications of surgery classified according to Clavien-Dindo classification of surgical complications.Table 4Clavien Dindo GradeNumber of patients (%)**I**n = 0 (0)**II**n = 1 (3.5)**III**n = 3 (11)**IV**n = 1 (3.5)**V**n = 1 (3.5)

The 30-day and 90-day mortality rates for all patients undergoing LHT was 0% and 3.5% (n = 1) respectively. Survival at 1, 3 and 5 years was 92% (n = 26/28); 68% (n = 19/28); and 53% (n = 9/17) respectively. Mean OS for all patients undergoing LHT was 117 months (range 2.5--180 months; [Fig. 1](#fig1){ref-type="fig"}). By tumour type, there was no significant difference in OS between groups ([Fig. 2](#fig2){ref-type="fig"}). However, patients having LHT for CRLM tended to do better than those with CCA or other primary tumours. [Table 5](#tbl5){ref-type="table"} shows short and long-term outcomes for patients according to their underlying pathology.Fig. 1Overall survival for all patients undergoing LHT One, Three and Five-year survival rates 92%, 68% and 53% respectively with a median overall survival of 117.3 months (IQ range 84.6--149.9 months).Fig. 1Fig. 2Survival curves according to tumour type (colorectal liver metastases, CRLM; cholangiocarcinoma, CC; and other pathology). Median Survival CRLM 122.6 months (IQR 86.4--158.7), CCA 66.7 months (IQR 20.5--112.0), Other 30.4 (IQR 19.8--40.9). P.Fig. 2Table 5Short- and long-term outcomes of patients undergoing LHT for all tumour types.Table 5Colorectal liver metastases (CRLAM; %)Cholangiocarcinoma (CC; %)Other pathology (HCC, NET, breast; %)**30 day mortality**n = 0/20 (0)n = 0/4 (0)n = 0/4 (0)**90 day mortality**n = 0/20 (0)n = 1/4 (25)n = 0/4 (0)**1 year survival**n = 20/20 (100)n = 3/4 (75)n = 3/4 (75)**3 year survival**n = 10/16 (62.5)n = 3/4 (75)n = 1/2 (50)**5 year survival**n = 10/15 (66)n = 3/4 (75)n = 0/1 (0)

Statistical analysis was performed to assess for factors associated with post-operative complications in LHT ([Table 6](#tbl6){ref-type="table"}) and OS ([Table 7](#tbl7){ref-type="table"}). Both patient and peri-operative factors were assessed. Analysis of our results found that an initial post-operative lactate of \>1.5 mmol/L was associated with an increased risk of developing post-operative complications (p = 0.035). The Pringle manoeuvre was used in 9 patients undergoing LHT (32%), however this was not found to be statistically significant in the development of post-operative complications (p = 0.243). No other patient or peri-operative factors were found to be associated with increased post-operative complications, although patient age \>65 just fell short of reaching statistical significance (p = 0.078). No factors were found to affect OS in our cohort ([Table 7](#tbl7){ref-type="table"}). In total, 19 patients had an R0 resection. The unit classification for an R1 resection is a margin with \<1 mm clearance. There were 9 patients that were classified as having an R1 resection, whilst there were no R2 resections. As stated, resection margin status did not show any statistical significance with regards to OS.Table 6Factors associated with post-operative complications.Table 6ComplicationsUnivariable**Age (years)nYesNo***P* = 0.078\<6515610\>6513112  **Sex**n*P* = 0.172M18612F1019  **ASA***P* = 0.397I615II20615III202  **Primary Tumour***P* = 0.449CRLM20416Cholangiocarcinoma404Other413  **Adjuvant Chemotherapy***P* = 0.663Yes14410No14311  **Neo-adjuvant Chemotherapy***P* = 0.815Yes19514No927  **Jaundice***P* = 0.563Yes211No26521  **Duration of surgery***P* = 0.577270 min927\>270 min1346  **Intraoperative blood loss \>1L***P* = 0.503Blood loss \<1L17512Blood loss \> 1L1129  **Blood transfusion***P* = 0.595Yes615No22616  **Segment 1 resection***P* = 0.172Yes1046No18315  **Segment VI/VII metastasectomy***P* = 0.801Yes725No21516  **R1/0 resection***P* = 0.483R1936R019415  **Pringle manoeuvre***P* = 0.243Yes918No19613  **Pringle manoeuvre duration***P* = 0.595\<10 min22616\>10 min615  **Post-operative lactate*P* = 0.035**Lactate \>1.519712Lactate \<1.5909Table 7Factors associated with overall survival.Table 7Median survival (months)Range (months)Univariable**Age (years)n***P* = 0.216\<6516131.787.1--176.3\>651263.835.4--92.2  **Sex**n*P* = 0.958M18123.884.8--162.8F1078.250.7--105.7  **ASA***P* = 0.553I647.629.6--65.5II--III22124.588.6--160  **Adjuvant Chemotherapy***P* = 0.411Yes14135.195.1--107.1No1463.936.5--91.2  **Neo-adjuvant chemotherapy***P* = 0.602Yes19130.194.9--165.4No961.630.0--93.1  **Post-op Complications**P = 0.998Yes763.837.2--90.3No21115.879.7--152.1  **R0/R1 resection**P = 0.267R0 resection19102.460.3--144.5R1 resection971.453.2--89.7  **Duration of surgery**P = 0.572270 min954.139.5--68.6\>270 min1361.741.8--81.7  Blood lossP = 0.282\<1L17129.790.5--169.0\>1L1150.227.8--72.7  **Blood transfusion**P = 0.504Yes645.727.6--63.9No22125.790.3--161.1  **Segment 1 resection**P = 0.219Yes1091.263.6--118.8No18104.664.2--145.0  **Segment VI/VII metastasectomy**P = 0.244Yes775.958.2--93.6No21106.168.7--143.7  **Pringle manoeuvre**P = 0.262Yes9145.8100--191.6No1955.039.1--70.9  **Duration of Pringle manouevre**P = 0.299\<10 min22105.466.9--144.0\>10 min697.584.7--149.9  **Post-operative lactate**P = 0.246\<1.5992.665.4--119.7\>1.51995.951.5--140.4

4. Discussion {#sec4}
=============

In this case series, we reviewed the short and long-term outcomes of patients undergoing LHT at RSCH, Guildford, UK. Previous published data has identified pre-operative jaundice and intraoperative blood transfusion as independent predictors of post-operative morbidity \[[@bib6],[@bib11],[@bib12]\]. We did not find pre-operative jaundice to be a predictor, but only 2 patients were jaundiced and both were stented prior to LHT. Data from our series identified a raised post-operative lactate of \>1.5 as a predictor for post-operative complications (p = 0.035). No other factors were identified.

The overall incidence of post-operative complications after LHT was 21% (n = 6) and is low, especially given the extent of hepatic resection undertaken during the procedure. Other series of LHT have quoted complication rates of more than 45% \[[@bib5],[@bib6],[@bib8]\]. These included transient hepatic insufficiency, bile leak and post-operative chest infection. Only one of our patients required return to theatre, for laparotomy and washout due to a bile leak. Only one patient in our series required pre-operative PVE, whilst two patients underwent pre-operative biliary drainage by PTC (with one having attempted drainage with ERCP in the first instance) prior to LHT. The majority of patients receiving neo-adjuvant chemotherapy were those with CRLM, whilst two patients with other pathology (metastatic NET and metastatic breast cancer) also received pre-operative chemotherapy. There was no consensus on the type of chemotherapy regimen received.

Overall 30 and 90-day mortalities of zero and 3.5% are also well within rates of 7% and 9% quoted by other series \[[@bib6],[@bib8]\]. One, three and five-year survival rates of 92%, 68% and 53% are also very reassuring, and are better than other series \[[@bib5],[@bib6],[@bib13],[@bib14]\], further supporting the safety of the procedure and its utilisation in the management of patients with a large tumour burden. The median OS for all patients undergoing LHT at our centre was 117.3 months (range 2.5--180 months). The median OS for patients with CRLM was 122.6 months (range 86.4--158.7 months). Although OS rates were improved in this group, compared to those undergoing LHT for CCA and other tumours, it did not reach statistical significance. This data compares favourably to other series of LHT for CRLM \[[@bib15]\] and adds further weight to evidence that LHT can provide an excellent long-term survival in these patients.

There was one patient death within 90 days of surgery. This patient had an underlying diagnosis of CCA and underwent LHT, including resection of the caudate lobe. Post-operatively the patient had persistently elevated liver function tests with bilirubin \>300 μmol/L and ALP \>400 IU /L for more than five days post-operatively and required multi-organ support in the intensive care unit. The patient was referred for porto-caval shunting due to "small for size syndrome" and liver insufficiency at a neighbouring institution. However, the patient developed vasopressor resistant sepsis and died shortly after this.

One of the major risks associated with hepatic resection is blood loss \[[@bib6],[@bib11],[@bib12]\]. Dionigi et al. \[[@bib16]\] found an increased rate of complications in patients undergoing hepatic resection that required peri-operative transfusion. The median blood loss in our series was 750 ml (range 300--2400 ml) and 6 patients (21%) required peri-operative transfusion. Of these, one patient experienced a bile leak post-operatively and this was managed conservatively by radiological drain insertion. We found that peri-operative transfusion was not associated with a reduction in OS. However, our findings regarding peri-operative transfusion are limited by the relatively small sample size of this cohort. Our data for blood loss is lower than that quoted in a study by Zhou et al., in which the mean blood loss in patients undergoing trisectionectomy was 1351 ml \[[@bib17]\]. Our results suggest a favourable surgical and anaesthetic technique. Notably, the threshold for transfusion was haemoglobin \<7.5 g/dL, or \<10 g/dL in patients with coronary artery disease or symptomatic anaemia. Despite such an extensive resection, very few patients required a blood transfusion and this may account for the low rate of complications and improved survival outcomes compared to other LHT series.

The data from our series would suggest that despite undergoing such an extensive resection, LHT is a relatively safe procedure and provides excellent survival outcomes for patients with CRLM.

4.1. Limitations {#sec4.1}
----------------

The study is limited by its small sample size, and therefore the lack of predictors for post-operative morbidity and mortality may be a Type II statistical error.

5. Conclusions {#sec5}
==============

In this small case series, we show that LHT is an effective treatment in patients with CRLM and significant tumour burden offering excellent OS.
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